FluMist Quadrivalent

Vaccine: FluMist Quadrivalent
Company: AstraZeneca
Approval Date: Feb. 29
Protects Against: Influenza

AstraZeneca ($AZN), maker of the nasal spray vaccine FluMist, nabbed FDA approval for a quadrivalent version of the flu vaccine Feb. 29. FluMist Quadrivalent not only covers two strains of influenza A and one strain of influenza B, but it also adds protection against a second strain of influenza B. This should increase efficacy because it gives health experts and vaccine manufacturers another shot at matching a circulating strain with a strain in the vaccine. Plus, the nasal spray appeals to many who shy away from the jab of a needle.

AstraZeneca compared the quadrivalent verision with the trivalent FluMist, finding that both maintained similar safety levels. Adding the extra strain did not affect immune response.

For more:
AstraZeneca's FluMist Quadrivalent to hit U.S. market
SLU: Include both strains of influenza B in shot

FluMist Quadrivalent

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.